Literature DB >> 33664567

The Impact of Treatment Adherence on Quality of Life Among Type 2 Diabetes Mellitus Patients - Findings from a Cross-Sectional Study.

Abdul Majeed1, Muhammad Rehman1, Iltaf Hussain1, Imran Imran2, Muhammad Usman Saleem3, Hamid Saeed4, Furqan K Hashmi4, Muqarrab Akbar5, Muhammad Asad Abrar1, Basit Ramzan6, Muhammad Omer Chaudhry7, Muhammad Islam4, Naveed Nisar8, Muhammad Fawad Rasool1.   

Abstract

AIM: The current study was conducted to assess the factors contributing to treatment adherence and its impact on the quality of life (QoL) in type 2 diabetes mellitus (T2DM) patients.
METHODS: A cross-sectional study was conducted between January 2020 to March 2020 among T2DM patients. The data was collected from T2DM out-patient clinics. The participants were recruited by using a simple random sampling method. To assess the association of demographics with the level of adherence, binary logistics regression analysis was applied. Moreover, the Mann-Whitney U-test was used to evaluate the impact of adherence on QoL.
RESULTS: A total of 384 patients participated in this study. Amongst them, 60.2% were male and 39.8% were female. Low adherence was seen in illiterate patients and patients older than 40 years. The results showed that good QoL in T2DM patients was significantly associated with treatment adherence (p= 0.004).
CONCLUSION: The finding of the current study showed that the non-adherence prevailed in illiterate strata of the study population and the medication adherence significantly affects the QoL in T2DM patients. These findings suggest that health regulatory agencies should focus on implementing disease-education interventions for improving the adherence to medications in patients with long-term conditions.
© 2021 Majeed et al.

Entities:  

Keywords:  drug adherence; quality of life; type 2 diabetes

Year:  2021        PMID: 33664567      PMCID: PMC7924113          DOI: 10.2147/PPA.S295012

Source DB:  PubMed          Journal:  Patient Prefer Adherence        ISSN: 1177-889X            Impact factor:   2.711


Introduction

The prevalence of long-term conditions is increasing with every passing day, as 50% of the visits in primary care clinics are attributed to these conditions.1 It has been reported that 70% of the total health budget is consumed by patients having long-term conditions.1 Since patients diagnosed with long-term conditions have to receive treatment for a long period, therefore the adherence to treatment and the quality of life (QoL) have become important parameters for assessing the effectiveness of the disease management plan. The improvement of patients’ QoL is very important in the management of long-term conditions, as the poor QoL may lead to the development of disease-associated complications.2 Adherence is the integral component for the implementation of pharmacological and non-pharmacological approaches, and it plays an essential role in the effective management of long-term diseases. However, medication non-adherence is a common problem in patients with long-term conditions.3,4 Studies have shown that adherence to medications is generally higher in patients with an acute illness, as compared to patients with chronic diseases.3,5–7 Adherence to medications is around 50% in the developed world and it is expected to be lower in the developing world.8 The patient and medication-related factors associated with treatment non-adherence have been reported in the literature.9 QoL is a multidimensional parameter that encompassing the emotional, physical, material, and social well-being of the individual.10,11 The healthcare providers goal of therapy in long-term conditions is to maintain or improve the health-related or disease-related QoL.12 The QoL is not only associated with the disease manifestations but it is also related to the patient’s perception toward their illness.13 To improve patient’s QoL in long-term conditions, the goal should be to provide personalized care by actively involving them in designing their treatment plans and considering their personal preferences.10 According to the world health organization (WHO), Pakistan, in 2019, ranked at fourth position with a diabetic population of 19.4 million.14 It is estimated that in 2030, this number will increase to 26.2 million, and in 2045, it will be ranked number third in the world with a projected diabetic population of 37.12.15 Most of the patients are suffering from type 2 diabetes mellitus (T2DM) which comprises 90% of all diabetes mellitus cases in the world. T2DM is spreading at an alarming rate in Pakistan, therefore it is the need of time to take drastic steps towards its management and improving medication adherence among the diabetic population.14,15 In Pakistan, limited information is available regarding the assessment of drug adherence with the QoL of T2DM patients.16 Therefore, if a study is conducted that can assess the impact of treatment adherence with the QoL in T2DM patients, it can be of great clinical importance. The current study was conducted to assess the factors contributing to treatment adherence and its effect on the QoL of T2DM patients.

Method and Instruments

Study Design, Setting, and Participants

A cross-sectional study was conducted between January 2020 to March 2020. Study participants were T2DM patients. The study was conducted in the outpatient diabetic clinics of Multan, Pakistan. The patients having T2DM with age greater than 25 years, and a diabetic history of more than 1 year were included in this study. The patients were enrolled in the study after signing an informed consent form.

Sample Size and Sampling Method

According to the International Diabetes Federation (IDF), the prevalence of T2DM in Pakistan was 17.1% in 2019.17 Therefore, a prevalence-based sample size was calculated by using the Raosoft online sample size calculator (Raosoft, Inc. USA)18 A sample size of 384 was obtained with a margin of error of 5%, and a Confidence level of 95%. The simple random sampling technique was utilized for the selection of study participants.

Ethical Consideration

This study was performed in accordance with the ethical standard of the institution and the Declaration of Helsinki and was approved by the ethical committee of the department of pharmacy practice, Bahauddin Zakariya University, Multan, Pakistan (Reference No: Acad/PRAC/18-20/20). To ensure the privacy and anonymity of patients, their names were replaced by a sequence of allotted numbers. Moreover, the data in hard form were kept in the departmental laboratory locker.

Study Instrument

In the present study, two instruments were used ie drug attitude inventory- 10 (DAI-10) to assess the treatment adherence and EQ-5D-5L to assess the QoL. Both scales were used after getting the permission.

DAI-10

DAI-10 scale is a self-administered and pre-validated scale that comprises of 10 questions based on True/ False responses.19,20 In this scale, a 1-point score is awarded to a correct response, and the total score greater than 7 shows high adherence, and a score less than 7 shows low adherence.

QoL Scale

The QoL scale EQ-5D-5L21 consisted of five (5) domains that include mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression. Each domain is comprised of five levels of severity, which include: no problem, slight problem, moderate problem, severe problem, and extreme problem. The EQ-5D preference weight for each health state was not available for the Pakistani population. Therefore, the states were derived from time trade-off (TTO) tariff of preference weights from the general population of the United Kingdom.22

Data Collection Procedure

The participants were randomly selected from the outpatient diabetic clinics from selected hospitals of Multan during their visit to the health care providers. Informed consent was taken from each patient before being included in the study, ensuring confidentiality, and describing to them the objectives of the study. Incomplete questionnaires were not included in the final analysis. The numbers of excluded questionnaire were sixty-six. The process of data collection is shown in Figure 1.
Figure 1

The data collection process.

The data collection process.

Statistical Analysis

The statistical package for Social Sciences (SPSS) v 25 (Inc., Chicago, USA) was used for statistical analysis. Descriptive statistics were used to summarize the data. The general linear multivariate analysis model (GLM) was used to predict the significant differences between the independent and dependent variables, whereas the Mann–Whitney-U test was used to assess the impact of adherence level on QoL.

Results

Demographic Characteristics of the Participants

A total of 384 patients participated in this study. The age of most participants was greater than 40 years (77.1%). The majority of the participants were male (60.2%) and residing in urban areas (59.9%). Most of the participants were married (95.8%) and illiterate (34.1%). One twenty-one participants were jobless (31.5%). The majority of the participants were using oral medications (52.1%), followed by insulin (25.8%) and 22.1% were taking both insulin and oral medications. The detailed demographics are provided in Table 1.
Table 1

Demographic Characteristics of the Participants

Characteristics of the ParticipantsFrequencyPercentage
Age25–408822.9
>4029677.1
GenderMan23160.2
Woman15339.8
Marital statusMarried36895.8
Unmarried164.2
Education levelIlliterate13134.1
Primary379.6
Secondary4712.2
Graduate9925.8
Postgraduate7018.2
OccupationPublic-sector job6115.9
Private-sector job10928.4
Business9324.2
Unemployed12131.5
ResidenceRural15440.1
Urban23059.9
TreatmentOral20052.1
Insulin9925.8
Oral + insulin8522.1
Demographic Characteristics of the Participants

Medication Adherence

The majority of the participants gave a positive response regarding the good and beneficial use of medications (62.0%) and most of the participants showed fear while taking medications (44.5%). The majority of the participants were using medication of their choice (38%) and they believed that the medications make them calmer and more relaxed (73.4%). The majority of the participants complained of sluggish and lazy behavior due to medication use (38.5%) and most of the participants fell normal when they use their medication (76.3%). The participant responses to the DAI-10 scale can be seen in Table 2.
Table 2

The Participant Responses to DAI-10 Scale

QuestionsFrequencyPercentage
Q1True29877.6
Q2True17344.5
Q3True14638.0
Q4True28273.4
Q5True14838.5
Q6True11329.4
Q7True29376.3
Q8True25065.1
Q9True10126.3
Q10True25165.4
The Participant Responses to DAI-10 Scale

Impact of Demographics on QoL and Drug Adherence

In the current study, a significant difference was seen in age (p <0.001) and residency (p = 0.041) of the participants to their QoL. Moreover, concerning drug adherence, there was a significant difference across marital status and level of education of the participants. The detail is given in Table 3.
Table 3

The Association of Demographics with the Level of Adherence and Quality of Life by Using the Multivariate Analysis

SourceDependent VariableMean SquareF-valueP-value
AgeQoL1202.07100.36.<0.001*
Drug Adherence0.1420.040.842
GenderQoL38.9373.0450.124
Drug Adherence0.2220.0820.783
Marital statusQoL4.040.3370.56
Drug Adherence31.118.710.003*
Educational levelQoL7.6320.5970.677
Drug Adherence42.01215.4780.001*
OccupationQoL14.8751.1630.389
Drug Adherence0.5570.2050.890
TreatmentQoL16.8371.3170.327
Drug Adherence3.4641.2760.337
ResidenceQoL80.0806.2630.041*
Drug Adherence0.0510.0190.895

Note: *p<0.05.

Abbreviation: QoL, quality of life.

The Association of Demographics with the Level of Adherence and Quality of Life by Using the Multivariate Analysis Note: *p<0.05. Abbreviation: QoL, quality of life.

QoL

In terms of mobility, most of the participants were having no problem (44%) followed by a slight (29.2%) and moderate problem (21.4%). The majority of participants had a slight problem in performing self-care (34.1%) while 56.3% had a slight problem in carrying usual activities. Most of the participants felt pain/discomfort (49.5%) and depression (38%). The QoL of the participants can be seen in Table 4.
Table 4

The Quality of Life of the Participants

Level of ProblemsQoL Domains
MobilitySelf-CareUsual ActivityPain/ DiscomfortAnxiety/ Depression
Level 1 (No Problem)169(44%)178(46.4%)72(18.8%)60(15.6%)93(24.2%)
Level 2 (Slight Problem)112(29.2%)131(34.1%)216(56.3%)190(49.5%)146(38%)
Level 3 (Moderate Problem)82(21.4%)62(16.1%)60(15.6%)66(17.2%)70(18.2%)
Level 4 (Severe Problem)21(5.5%)13(3.4%)30(7.8%)29(7.6%)38(9.9%)
Level 5 (Extreme problem)006(1.6%)39(10.2%)37(9.6%)
The Quality of Life of the Participants A total of 46 different health states were reported by the study participants, whereby 13 (3.4%) showed no problems in all five domains while 124 (32.4%) respondents pointed out no problem in mobility and self-care domain while moderate problem in pain and anxiety/depression domain ().

Impact of Level of Adherence on QoL

The independent-samples Mann Whitney U-test revealed that the good quality of life in T2DM patients was significantly associated with a high level of adherence (p= 0.004) ().

Discussion

In the present study, we have assessed the relationship between treatment adherence and QoL of T2DM patients. Our results showed that the marital status and level of literacy were significantly associated with treatment adherence. Moreover, it was observed that the good QoL in the T2DM patients was associated with higher medication adherence rates. Adherence to the treatment is an important factor in the management of chronic conditions.23 Poor medication adherence is a major barrier to the management of T2DM. Poor medication adherence is also associated with health expenditures.24 The medication adherence rate identified in this study was 33.3%. This number was low as compared to a similar study from the United State of America (79%),25 but it was consistent with a study reported from Indonesia (29.7%).26 This comparison indicates that in developed countries, there is a well-established healthcare system where the healthcare team works together to deliver health and provide individualized treatment (if needed) to the patients. While in developing countries with a focus on Pakistan, due to poor healthcare system, poor quality of pharmaceutical care to the patients, and an increase in the cost of therapy may contribute to the low treatment adherence in the T2DM population. The incorporation of pharmaceutical care in the healthcare system has significantly contributed to treatment adherence in patients with long-term conditions.27 It has been reported that the participants with a higher lower literacy level, living with the disease for a long time had a negative effect on their QoL and treatment adherence.26,28 In the current study, it was seen that the literacy level of the participants was significantly associated with higher treatment adherence and that is consistent with the previous reports.29,30 This finding highlights the need for focused health literacy programs in the illiterate stratum of the community. In the current study, most of the participants report slight to moderate problems in terms of QoL. This finding was similar to the reported studies from Pakistan16 and Indonesia.26 The QoL in T2DM patients is an important outcome parameter. Therefore, it is the primary goal of the healthcare providers to formulate sustainable health goals for the betterment of QoL of diabetic patients.31 Patients with chronic conditions are more likely to have physical, psychological, and social health issues as compared to patients with acute illnesses.32–34 In this study, a positive relationship between QoL and treatment adherence was seen in T2DM patients. The patients with poor treatment adherence showed a lower QoL and those with good treatment adherence showed a good QoL. This result was consistent with the previous reports in which the DAI-10 scale was used with similar cutoff-points.33,34 Moreover, medication adherence can be improved by focusing on patient counseling, disease education, and by decreasing the complexity of the prescribed dosing regimen. According to WHO, improving adherence to treatment in chronic conditions can significantly produce health and economic benefits.35 Treatment non-adherence leads to disease-related complications and can increase the direct and indirect healthcare costs.3 It is reported that in adults, around 10% of hospital admissions can be attributed to treatment non-adherence.36 Moreover, the 10% increase in treatment adherence in diabetic patients can decrease the annual healthcare costs by 8.6–28.9%.35 Also, non-adherence to medication can develop an uncontrolled disease condition that can have a considerable effect on patients’ QoL, as it may lead to physical, social, and financial problems.37

Practice Implications and Future Recommendation

The present study can have many implications at the national and global levels. The poor QoL and treatment non-adherence in T2DM patients is alarming. The Physician and Pharmacist should emphasize the importance of treatment adherence in the management of chronic conditions to their patients. Moreover, the barriers to treatment adherence in patients with chronic conditions can be addressed by allowing their active participation in designing personalized disease management plans.

Conclusion

The current study showed that T2DM patients with a higher level of treatment adherence showed good QoL. Moreover, the literacy level of T2DM patients was significantly associated with their level of adherence. The treatment adherence can be improved by simplifying the prescribed dosing regimen and ensuring appropriate patient counseling. To increase treatment adherence in T2DM patients, there is a need for the initiation of diabetes education programs at the community levels.
  25 in total

1.  Persistence with treatment for hypertension in actual practice.

Authors:  J J Caro; M Salas; J L Speckman; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

2.  Evaluation of a Quality Improvement Resource for Public Health Practitioners.

Authors:  Deborah S Porterfield; Laura H Marcial; Stephen Brown; Cynthia Throop; Jamie Pina
Journal:  Public Health Rep       Date:  2017-01-30       Impact factor: 2.792

3.  Does adherence to the therapeutic regimen associate with health related quality of life: Findings from an observational study of type 2 diabetes mellitus patients in Pakistan.

Authors:  Saeedur Rashid Nazir; Mohamed Azmi Hassali; Fahad Saleem; Sajid Bashir; Hisham Aljadhey
Journal:  Pak J Pharm Sci       Date:  2017-11       Impact factor: 0.684

4.  Helping patients follow prescribed treatment: clinical applications.

Authors:  R Brian Haynes; Heather P McDonald; Amit X Garg
Journal:  JAMA       Date:  2002-12-11       Impact factor: 56.272

5.  Utilization of oral hypoglycemic agents in a drug-insured U.S. population.

Authors:  S J Boccuzzi; J Wogen; J Fox; J C Sung; A B Shah; J Kim
Journal:  Diabetes Care       Date:  2001-08       Impact factor: 19.112

Review 6.  The Royal College of Physician's Quality Improvement Hub - how can it help physicians to improve patient care?

Authors:  Mohsin I Choudry; Kevin Stewart; Tricia Woodhead
Journal:  Future Hosp J       Date:  2016-10

7.  Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus.

Authors:  Hua Shao; Guoming Chen; Chao Zhu; Yongfei Chen; Yamin Liu; Yuxing He; Hui Jin
Journal:  Patient Prefer Adherence       Date:  2017-05-08       Impact factor: 2.711

8.  Non-adherence to self-care practices & medication and health related quality of life among patients with type 2 diabetes: a cross-sectional study.

Authors:  Farzana Saleh; Shirin J Mumu; Ferdous Ara; Md Abdul Hafez; Liaquat Ali
Journal:  BMC Public Health       Date:  2014-05-07       Impact factor: 3.295

9.  The association between health literacy levels and patient-reported outcomes in Japanese type 2 diabetic patients.

Authors:  Haruka Ueno; Hirono Ishikawa; Ryo Suzuki; Yoshihiko Izumida; Yumiko Ohashi; Toshimasa Yamauchi; Takashi Kadowaki; Takahiro Kiuchi
Journal:  SAGE Open Med       Date:  2019-07-23

10.  Investigation of the quality of life of patients with hypertension in health centers.

Authors:  Farbod Ebadi Fard Azar; Mahnaz Solhi; Fakhreddin Chabaksvar
Journal:  J Educ Health Promot       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.